Perseus Proteomics Inc. (President: Akiyuki Furuya; hereafter, Perseus), a subsidiary of FUJIFILM Corporation (President and CEO: Shigetaka Komori), has developed a new anti-lung carcinoma antibody. The achievement was announced on April 19 (April 20, Japan time) in the annual meeting of the American Association for Cancer Research*1, convened in Washington D.C., United States.
Perseus found the protein which specifically expressed in cancer tissue by analyzing human gene expression profiling*2, collaborating with the Research Center for Advanced Science and Technology, University of Tokyo. Perseus showed the protein is expressed specifically in cancer tissues such as lung, pancreatic and colon but not in normal tissues. Perseus successfully generated an antibody against the protein, and confirmed that the antibody showed a significant anti-tumor effect for lung cancer tissue in mouse models*3
The Fujifilm Group is amassing its resources to develop this antibody further as a promising candidate for antibody for lung cancer therapy. The Group will continue to tap into its advanced technologies and rich experiences to deliver optimum solutions featuring proprietary technologies, and to further improve people's quality of life.
Established as a biopharmaceutical bio-venture company, a division of the Research Center for Advanced Science and Technology at the University of Tokyo. The company became a subsidiary of Fujifilm (equity ratio: 77%) in December 2008.